Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Jürg Bernhard(International Breast Cancer Study Group), Barbara Walley, Fabio Puglisi(University of Udine), Meredith M. Regan(Dana-Farber Cancer Institute), Lorenzo Pavesi(University of Trento), Vani Parmar(Homi Bhabha National Institute), Prudence A. Francis(Peter MacCallum Cancer Centre), Richard D. Gelber(Harvard University), Gini F. Fleming(University of Chicago Medical Center), Carlo Tondini(Ospedale Papa Giovanni XXIII), Marco Colleoni(European Institute of Oncology), Harold J. Burstein(Dana-Farber Cancer Institute), Simon Spazzapan(Centro di Riferimento Oncologico), Olivia Pagani(Swiss Group For Clinical Cancer Research), Alan S. Coates(International Breast Cancer Study Group), Karen N. Price(International Breast Cancer Study Group), Weixiu Luo(Dana-Farber Cancer Institute), Graziella Pinotti(Medica (Italy)), Karin Ribi, Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Thomas Ruhstaller(University Hospital Bonn)
Cited by 179
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k